PTC Therapeutics, Inc. (NASDAQ:PTCT) headquartered in South Plainfield, will host a conference call for the investment community to discuss the 3Q20 earnings result on 29th October 2020 at 4:30 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.ptcbio.com
Earnings Expectation
PTC Therapeutics, Inc. is set to announce third quarter earning results on Thursday 29th October 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, PTCT to report 3Q20 loss of $ 0.06 per share. For the full year, analysts anticipate top line of $ 367.87 million, while looking forward to loss of $ 5.52 per share bottom line.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients.
